Isatuximab Added to RVd Boosts Response in New Myeloma
The addition of the anti-CD38 antibody improved minimal residual disease rates at the end of induction, a marker for better outcomes following autologous stem cell transplant.
Medscape Medical News
source https://www.medscape.com/viewarticle/964650?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/964650?src=rss
Comments
Post a Comment